Literature DB >> 19458010

Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

Lautaro G Perez1, Matthew R Costa, Christopher A Todd, Barton F Haynes, David C Montefiori.   

Abstract

Receptors (FcgammaRs) for the constant region of immunoglobulin G (IgG) are an important link between humoral immunity and cellular immunity. To help define the role of FcgammaRs in determining the fate of human immunodeficiency virus type 1 (HIV-1) immune complexes, cDNAs for the four major human Fcgamma receptors (FcgammaRI, FcgammaRIIa, FcgammaRIIb, and FcgammaRIIIa) were stably expressed by lentiviral transduction in a cell line (TZM-bl) commonly used for standardized assessments of HIV-1 neutralization. Individual cell lines, each expressing a different FcgammaR, bound human IgG, as evidence that the physical properties of the receptors were preserved. In assays with a HIV-1 multisubtype panel, the neutralizing activities of two monoclonal antibodies (2F5 and 4E10) that target the membrane-proximal external region (MPER) of gp41 were potentiated by FcgammaRI and, to a lesser extent, by FcgammaRIIb. Moreover, the neutralizing activity of an HIV-1-positive plasma sample known to contain gp41 MPER-specific antibodies was potentiated by FcgammaRI. The neutralizing activities of monoclonal antibodies b12 and 2G12 and other HIV-1-positive plasma samples were rarely affected by any of the four FcgammaRs. Effects with gp41 MPER-specific antibodies were moderately stronger for IgG1 than for IgG3 and were ineffective for Fab. We conclude that FcgammaRI and FcgammaRIIb facilitate antibody-mediated neutralization of HIV-1 by a mechanism that is dependent on the Fc region, IgG subclass, and epitope specificity of antibody. The FcgammaR effects seen here suggests that the MPER of gp41 could have greater value for vaccines than previously recognized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458010      PMCID: PMC2708617          DOI: 10.1128/JVI.00656-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  110 in total

Review 1.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

3.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Characterization and expression of the gene for the human Fc receptor gamma subunit. Definition of a new gene family.

Authors:  H Küster; H Thompson; J P Kinet
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

6.  Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus.

Authors:  K E Sullivan; A F Jawad; L M Piliero; N Kim; X Luan; D Goldman; M Petri
Journal:  Rheumatology (Oxford)       Date:  2003-03       Impact factor: 7.580

7.  Human immunodeficiency virus infection of monocytes: relationship to Fc-gamma receptors and antibody-dependent viral enhancement.

Authors:  J Laurence; A Saunders; E Early; J E Salmon
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

10.  Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice.

Authors:  I A Heijnen; M J van Vugt; N A Fanger; R F Graziano; T P de Wit; F M Hofhuis; P M Guyre; P J Capel; J S Verbeek; J G van de Winkel
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more
  49 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

4.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

5.  Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors:  Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

6.  Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.

Authors:  Zhongyu Zhu; Haiyan Rebekah Qin; Weizao Chen; Qi Zhao; Xiaoying Shen; Robert Schutte; Yanping Wang; Gilad Ofek; Emily Streaker; Ponraj Prabakaran; Genevieve G Fouda; Hua-Xin Liao; John Owens; Mark Louder; Yongping Yang; Kristina-Ana Klaric; M Anthony Moody; John R Mascola; Jamie K Scott; Peter D Kwong; David Montefiori; Barton F Haynes; Georgia D Tomaras; Dimiter S Dimitrov
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

7.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

8.  4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms.

Authors:  Kyle J Nakamura; Johannes S Gach; Laura Jones; Katherine Semrau; Jan Walter; Frederic Bibollet-Ruche; Julie M Decker; Laura Heath; William D Decker; Moses Sinkala; Chipepo Kankasa; Donald Thea; James Mullins; Louise Kuhn; Michael B Zwick; Grace M Aldrovandi
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

Review 9.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

10.  Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Authors:  Zoltan Beck; Bruce K Brown; Lindsay Wieczorek; Kristina K Peachman; Gary R Matyas; Victoria R Polonis; Mangala Rao; Carl R Alving
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.